Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3495)	12/31/1997 1:55:00 PM
From: Izzy	Read Replies (2) \| Respond to of 6136

JLL: Since we have the time and considering the prior posts, tell me if you agree or disagree with some of the following comments. The bottom line is the qualifications and abilities/capabilities of the prescribing doctors, who must know when and how to initiate therapy, which drugs to order, and which drugs should or should not be prescribed together (drug-drug interactions). Current treatment is a combo of 2 or more drugs, yet some doctors are still prescribing monotherapy. "Polypharmacy" is unavoidable in treating HIV/AIDS patients. The best time to initiate treatment is during the acute stage of HIV infection, using triple-drug combo treatment as early as possible. Medications should be changed when there is toxicity, drug intolerance, or evidence of drug failure. For replacement therapy, never change to a single-drug but use 2 new drugs that have not been taken before, do not have cross-resistance with other meds, have different mechanisms of action, and have no overlapping toxicities or drug-drug interactions. Managing HIV/AIDS patients has become more complex. Patients should only be under the care of a physician who is absolutely current and knowledgeable on available antiretroviral therapies.